Background HER2-targeted therapies have substantially improved outcomes for patients
with HER2-positive breast and gastric or gastro-oesophageal junction cancers. Several other …

COVID-19, caused by SARS-CoV-2, continues to be a major health problem since its first
description in Wuhan, China, in December 2019. Multiple drugs have been tried to date in the …

BACKGROUND Men are 4 to 8 times more likely to develop hepatocellular carcinoma (HCC)
than women. Preclinical models have suggested a role for sex hormones in the …

Cancer cachexia is a multifactorial syndrome characterized by an ongoing loss of skeletal
muscle mass, which negatively affects quality of life and portends a poor prognosis. Numerous …

2500 Background: ZW25, a novel Azymetric bispecific antibody, targets HER2 domains ECD2
and ECD4, resulting in multiple differentiated mechanisms of action including increased …

299 Background: Treatment options are limited for patients with unresectable, locally
advanced or metastatic BTCs progressing after first line treatment. Standard second line …

Colorectal cancer (CRC) is a heterogeneous disease with distinct molecular and clinical
features, which reflects the wide range of prognostic outcomes and treatment responses …

Hepatocellular carcinoma (HCC) is rising in incidence and remains a leading cause of
cancer-related death. After a decade of disappointing trials following the approval of sorafenib for …

Background: COVID-19 has several overlapping phases. Treatments to date have focused on
the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase …

… Funda Meric-Bernstam1; Erika Hamilton2; Murali Beeram3; Diana Hanna4; Anthony El-Khoueiry4;
Yoon-Koo Kang5; Keun-WookLee6; Jeeyun Lee7; Sun Young Rha8; Jose Chaves9; Do-Youn …